Core Viewpoint - ST Huluwawa (605199.SH) announced that its wholly-owned subsidiary, Guangxi Weiwei Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for the compound polyethylene glycol (3350) electrolyte oral solution, which is indicated for the treatment of chronic constipation and fecal impaction [1] Company Summary - ST Huluwawa's subsidiary Guangxi Weiwei has successfully obtained regulatory approval for a new product, enhancing its portfolio in the gastrointestinal treatment market [1] - The approved product, compound polyethylene glycol (3350) electrolyte oral solution, targets a significant health issue, chronic constipation, which may lead to increased market demand [1]

Core Viewpoint - The company ST HuLuWa has received approval from the National Medical Products Administration for its subsidiary Guangxi Weiwei Pharmaceutical Co., Ltd. to market a new oral solution for chronic constipation and fecal impaction, enhancing its product line [1] Group 1 - The approved drug is a compound polyethylene glycol (3350) electrolyte oral solution, developed by Norgine, and contains active ingredients such as polyethylene glycol 3350, sodium chloride, potassium chloride, and sodium bicarbonate [1] - The company has invested a total of RMB 762,100 in research and development for this drug [1] - The approval of the drug registration certificate will further enrich the company's product offerings [1]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-010 海南葫芦娃药业集团股份有限公司 关于全资子公司获得复方聚乙二醇（3350） 电解质口服溶液药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司全资子公司广西维威制药有限公司（以下简 称"广西维威"）近日收到国家药品监督管理局（以下简称"国家药监局"）核准签 发的关于复方聚乙二醇（3350）电解质口服溶液的《药品注册证书》。现将有关情况 公告如下： 一、药品基本情况 药物名称：复方聚乙二醇（3350）电解质口服溶液 剂型：口服溶液剂 注册分类：化学药品 3 类 规格：25ml/袋 上市许可持有人：广西维威制药有限公司 药品批准文号：国药准字 H20263335 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品研发及相关 复方聚乙二醇（3350）电解质口服溶液适用于治疗慢性便秘、粪便嵌塞。 复方聚乙二醇（3350）电解质口服溶液， ...

Group 1 - Intercontinental Oil and Gas focuses on oil exploration and development, with significant operations in Kazakhstan and the Malacca Strait, benefiting from the Hainan Free Trade Port's zero-tariff policy which will reduce equipment import costs and enhance cross-border energy trade efficiency, with a projected 30% increase in trade scale over the next three years [1][34] - Jinpan Technology, a leading manufacturer of high-end power distribution equipment, will benefit from reduced raw material costs and a 15% corporate income tax reduction, enhancing profitability and enabling expansion into the ASEAN power equipment market [2][35] - Hainan Airlines, a major player in the aviation sector, expects a significant increase in passenger traffic due to the visa-free policy for 86 countries and duty-free upgrades, with projected passenger volume exceeding 80 million by 2026 [3][36] Group 2 - Junda Co., a top photovoltaic cell manufacturer, anticipates growth in its solar business due to reduced equipment costs and tax incentives, with plans to participate in Hainan's integrated wind and solar storage projects [4][37] - Caesar Travel, a comprehensive tourism service provider, expects a doubling of cross-border tourism business and a significant increase in tourist arrivals, with projections of 180 million visitors by 2026 [5][38] - Xinda A, a diversified company focusing on motorcycle manufacturing and coal mining, aims to leverage the zero-tariff policy to enhance profitability and expand into the electric vehicle market [6][39] Group 3 - ST Huluwawa, a leading pediatric pharmaceutical company, will benefit from reduced raw material costs and tax incentives, with plans to expand into the ASEAN pharmaceutical market [8][40] - Hainan Ruize, a construction industry leader, anticipates a surge in infrastructure demand with projected investments exceeding 100 billion by 2026, benefiting from the Hainan Free Trade Port's policies [9][42] - Hainan Airport, a key player in airport operations, expects a doubling of cargo business and significant passenger growth due to the visa-free policy and duty-free upgrades [10][43] Group 4 - Hainan Development, an investment platform, anticipates a substantial increase in duty-free sales, projected to exceed 100 billion by 2026, benefiting from the Hainan Free Trade Port's policies [11][45] - Hainan Highway, a major highway operator, expects a significant increase in traffic volume, projected to exceed 200 million vehicles by 2026, benefiting from the integration of tourism and real estate [20][56] - Hainan Rubber, the world's largest natural rubber producer, aims to expand its market presence in ASEAN due to favorable trade policies and tax incentives [21][57]

Core Points - Beijing Rural Commercial Bank announced the public disclosure of its physical precious metals consignment business cooperation institutions for the year 2026 [1] Group 1: Announcement Details - The announcement aims to ensure transparency and inform stakeholders about the institutions involved in the physical precious metals business [1] - A list of cooperation institutions for 2026 includes various companies such as China Gold Coin Corporation and its subsidiaries, Beijing Caishikou Department Store Co., Ltd., and others [2] - The listed institutions have established formal cooperation with Beijing Rural Commercial Bank to conduct physical precious metals consignment business in 2026 [2] Group 2: Contact Information - Stakeholders can contact Beijing Rural Commercial Bank at hotline 96198 for any inquiries or further information regarding the cooperation institutions [2]

Group 1 - The company ST HuLuWa expects a net loss attributable to shareholders of the parent company between -210 million to -310 million yuan for the year 2025, indicating a decline compared to the same period last year [1] - The primary reasons for the performance change include adjustments in industry policies and market environment, leading the company to proactively modify the sales model for certain clients and optimize marketing channel layouts, resulting in decreased product sales and gross margin levels [1] - The completion and capitalization of the Haikou Meian Children's Medicine Intelligent Manufacturing Base and the second phase of the Guangxi Weiwei production base have led to increased fixed asset depreciation expenses, alongside rising bank loan interest expenses and ongoing R&D investments, which have negatively impacted the company's operating performance for the reporting period [1] Group 2 - Despite facing challenges from industry fluctuations, the company has implemented relevant countermeasures, including optimizing customer management, promoting customer tiered management, and enhancing cooperation depth with high-quality clients [1] - The company is also focusing on deepening cost control and improving operational efficiency through refined management practices, strictly controlling expenditure, and striving to enhance operating performance by reducing costs and increasing efficiency [1]

Core Viewpoint - ST HuLuWa announced an expected net profit attributable to shareholders of the listed company for the year 2025 to be between -210 million and -310 million yuan, indicating a significant loss forecast [1] - The company also projected a net profit attributable to shareholders after deducting non-recurring gains and losses for 2025 to be between -250 million and -350 million yuan, further emphasizing the anticipated financial challenges [1] Financial Projections - Expected net profit for 2025: -210 million to -310 million yuan [1] - Expected net profit after non-recurring items for 2025: -250 million to -350 million yuan [1]

一、关于公司被实施其他风险警示的基本情况 证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-008 海南葫芦娃药业集团股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 海南葫芦娃药业集团股份有限公司（以下简称"公司"）2024年度内部控制被 出具否定意见审计报告，根据《上海证券交易所股票上市规则》第9.8.1条规定，公司 股票于2025年4月30日起被实施其他风险警示。 ● 根据《上海证券交易所股票上市规则》第9.8.5条："上市公司股票因第9.8.1 条第一款第（二）项至第（五）项规定情形被实施其他风险警示的，在被实施其他风险 警示期间，公司应当至少每月披露1次提示性公告，分阶段披露涉及事项的解决进展情 况"。公司将每月披露一次其他风险警示相关事项的进展情况，提示相关风险。 8、公司围绕合规管理核心目标，积极加强与监管部门的沟通联系，加强风险防控 体系建设。组织核心人员参与监管政策解读会议，聚焦内部控制、信息披露等政策调整； ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-009 海南葫芦娃药业集团股份有限公司 关于全资子公司获得依巴斯汀口服溶液药品注册证书的 公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司全资子公司广西维威制药有限公司（以下简 称"广西维威"）近日收到国家药品监督管理局（以下简称"国家药监局"）核准签 发的关于依巴斯汀口服溶液的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药物名称：依巴斯汀口服溶液 剂型：口服溶液剂 注册分类：化学药品 3 类 规格：120ml：120mg 上市许可持有人：广西维威制药有限公司 受理号：CYHS2302665 药品批准文号：国药准字 H20263275 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品研发及相关 依巴斯汀口服溶液适用于伴有或不伴有过敏性结膜炎的过敏性鼻炎（季节性和 常年性）。慢性特发性荨麻疹的对症治疗。 截至目前，公司对该产品已 ...

Financial Performance Expectations - The company expects a net profit attributable to shareholders for 2025 to be between -210 million and -310 million RMB, indicating a loss compared to the previous year [3]. - The projected net profit after deducting non-recurring gains and losses is expected to be between -250 million and -350 million RMB for 2025 [5]. - In the previous year, the total profit was -269.17 million RMB, with a net profit attributable to shareholders of -274.46 million RMB [8]. - The company reported a loss per share of -0.69 RMB in the previous year [9]. Factors Affecting Performance - The decline in performance is attributed to adjustments in sales models and marketing channels due to industry policy changes and market environment shifts [10]. - Increased fixed asset depreciation from the completion of new manufacturing bases has contributed to the financial strain [10]. Operational Measures - The company is implementing measures to optimize customer management and enhance operational efficiency to improve performance [10]. Financial Data Disclosure - The financial data provided is preliminary and has not been audited by certified public accountants [11]. - Investors are advised to be cautious as the final audited financial data will be disclosed in the 2025 annual report [12].